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Abstract
Recent results by us and others have shown that the accessory protein Vpu determines plasma membrane versus endosomal accumulation of
the HIV-1 core protein Gag and progeny virions in the HeLa model of HIV-1 infection, since Vpu suppresses endocytosis of cell surface-
associated Gag. In this report, we used pulse-chase studies and subcellular fractionations to investigate endocytosis of newly synthesized Gag in
HeLa H1 cells. The uptake of Gag in ΔVpu-virus background was not blocked by inhibitors of clathrin-mediated endocytosis and
macropinocytosis. The cholesterol-sequestering drug filipin inhibited the uptake, but only if the drug was applied before extensive multimerization
of Gag had taken place. Thus, the uptake mechanism most likely is only indirectly dependent on cholesterol. Our results also indicated that
targeting phenotype of Gag was different in confluent versus subconfluent cell cultures, which could perhaps explain some of the controversies in
intracellular targeting of Gag.
© 2007 Elsevier Inc. All rights reserved.Keywords: HIV-1; Gag trafficking; Endocytosis; Vpu; Virus assemblyIntroduction
Assembly of human immunodeficiency virus type 1 (HIV-1)
is directed by the viral core protein precursor Gag (Pr55Gag)
(Göttlinger, 2001; Resh, 2005). Pr55Gag is a myristoylated,
peripheral membrane protein, and it binds to cellular mem-
branes and assembles into enveloped virus-like particles (VLPs)
independently of other viral proteins (Bryant and Ratner, 1990;
Gheysen et al., 1989; Göttlinger et al., 1989; Spearman et al.,
1994; Zhou et al., 1994), but release of progeny virions from
infected cells is enhanced by the viral accessory protein Vpu
(Bour and Strebel, 2003), and by the viral protease present in the
other core protein precursor, the Gag-Pol (Kaplan et al., 1994).
During or shortly after budding, Pr55Gag is cleaved into matrix,⁎ Corresponding author. Fax: +358 9 19126491.
E-mail address: maarit.suomalainen@helsinki.fi (M. Suomalainen).
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doi:10.1016/j.virol.2007.08.009capsid (CA), nucleocapsid, and p6 proteins and two peptides
SP1 and SP2 by the viral protease.
One intriguing aspect of the Gag-mediated assembly of
HIV-1 is that the assembly phenotype is cell type-dependent.
Electron microscopy (EM) and fluorescence microscopy
studies have indicated that Gag and progeny virions concen-
trate within large internal vacuoles in macrophages (Greene
Nguyen et al., 2003; Orenstein et al., 1988; Pelchen-Matthews
et al., 2003; Raposo et al., 2002). These vacuoles have been
assumed to represent late endosomes/multivesicular bodies, but
recent data indicate that they in fact are internally sequestered
plasma membrane domains (Deneka et al., 2007; Welsch et al.,
2007). In contrast, Gag and virus particles have been found
both at the plasma membrane and in internal, endosome-like
compartments in T cells and model cell lines such as 293T,
HeLa, and Cos (see, for example, Grigorov et al., 2006;
Nydegger et al., 2003; Sherer et al., 2003). The intracellular
route by which Gag reaches its cell surface or internal
localization, as well as the intracellular site where virus
assembly is initiated, have been subjects of intense debate.
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found to be continuous with the plasma membrane, the cell
surface is the primary site for HIV-1 assembly in these cells
(Deneka et al., 2007; Welsch et al., 2007). This conclusion is
supported by cell imaging and biochemical studies as well
(Jouvenet et al., 2006). The plasma membrane appears to be the
primary site for HIV-1 assembly in other cell types as well,
since several recent studies have provided strong evidence that
the internal Gag and virus particles in HeLa and 293T cells
originate from uptake of newly assembled virions from the cell
surface (Finzi et al., 2007; Harila et al., 2006; Jouvenet et al.,
2006; Neil et al., 2006). We and others recently identified the
viral accessory protein Vpu as an important determinant for
accumulation of Gag and progeny virions in internal
endosome-like compartments in HeLa H1 and HeLa cells
(Harila et al., 2006; Neil et al., 2006). The results from these
two studies indicated that a newly synthesized Gag was
initially inserted into the plasma membrane. When Gag was
coexpressed with Vpu, the protein remained at the plasma
membrane and progeny virions assembled at the cell surface
were efficiently released into the extracellular medium. In
contrast, Gag expressed in the absence of Vpu produced
progeny virions that remained tethered to the cell surface (Neil
et al., 2006), and the plasma membrane-associated newly
synthesized Gag, most likely in the form of a fully assembled
virion, was efficiently retargeted from the cell surface to an
internal endosome-like compartment by an as-yet-uncharacter-
ized uptake mechanism (Harila et al., 2006; Neil et al., 2006).
However, the initial insertion of newly synthesized Gag into
the plasma membrane is a controversial issue. Biarsenical/
tetracysteine labeling and cell imaging studies have favored
either direct insertion of Pr55Gag into the plasma membrane in
HeLa cells (Rudner et al., 2005), or provided evidence for
trafficking of newly synthesized Gag to the plasma membrane
via an endosomal intermediate (Perlman and Resh, 2006).
Furthermore, cell fractionation studies have indicated that a
newly synthesized Gag in 293T cells is first inserted into the
plasma membrane (Finzi et al., 2007), or that the protein
simultaneously reaches the plasma membrane and endosomal
membranes (Grigorov et al., 2006). Studies using Gag-green
fluorescent protein (Gag-GFP) molecules have suggested that
internalization from the plasma membrane accounts for
intracellular Gag in 293T cells and macrophages (Jouvenet
et al., 2006).
In the present study, we have investigated the endocytic
phenotype of Gag in HeLa H1 cells. Our results indicated that
the endocytosis of Gag in ΔVpu-background was not blocked
by an inhibitor of macropinocytosis [5-(N-ethyl-N-isopropyl)
amiloride], or by RNA interference (RNAi)-mediated knock-
down of clathrin heavy chain (CHC). The uptake was sensitive
to the cholesterol-sequestering drug filipin, but the effect of
filipin was most likely indirect and due to negative impact of the
drug on Gag multimerization and virus assembly. Notably, the
targeting phenotype of Gag in ΔVpu-background was found to
be different in confluent versus subconfluent cell cultures, since
newly synthesized Gag was simultaneously detected at the
plasma membrane and internal membranes in subconfluent cellswhereas targeting to the plasma membrane in confluent cells
clearly preceded the appearance of Gag in internal membranes.
Results
Impact of inhibitors of clathrin-mediated endocytosis and
macropinocytosis on the uptake of cell surface-associated Gag
Our previous results in HeLa H1 cells indicated that a newly
synthesized Pr55Gag was inserted into the plasma membrane,
but when expressed in the absence of Vpu, the protein
subsequently shifted from the cell surface to an internal
endosome-like compartment (Harila et al., 2006). Mammalian
cells have several endocytic routes which can be classified into
three main uptake modes: clathrin-mediated endocytosis,
macropinocytosis, and cholesterol-dependent (raft-mediated)
uptake (Marsh and Helenius, 2006; Pelkmans and Helenius,
2003). We used inhibitors of these three uptake modes to probe
the mechanism of Gag endocytosis in HeLa H1 cells.
RNAi-mediated knock-down of CHC was used to probe
whether the uptake of cell surface-associated Gag in ΔVpu-
virus background occurred by clathrin-mediated endocytosis.
HeLa H1 cells were transfected with CHC-specific siRNAs or
mock-transfected (i.e. treated only with the transfection
reagent), and the following day infected with vesicular
stomatitis virus (VSV) G-protein-pseudotyped NL4-3(Gag/
ΔVpu), a recombinant virus carrying a genome with a defective
Pol region and a defective vpu gene. Western blot analysis of
cell lysates after 24 h postinfection demonstrated that the CHC
siRNA effectively reduced intracellular levels of CHC (Fig.
1A). Biotin-tagged transferrin (TF) was used as a probe to
measure clathrin-dependent endocytosis in the infected CHC
knock-down cells. TF was initially bound to cells at cold, and
the cells were then shifted to 37 °C for 0, 5 or 15 min to allow
endocytosis. After incubation at 37 °C, cells were placed on ice,
and cell surface-associated TF was removed by trypsin. The
amount of trypsin insensitive, endocytosed TF was determined
by Western blot analyses of cell extracts. Both mock- and
siRNA-transfected cells bound ∼equal amounts of TF (Fig. 1B;
tot), and the TF at the cell surface was efficiently removed by
trypsin (the 0 min time point in Fig. 1B). After 5 min of
warming, TF had become fully resistant to trypsin in mock-
transfected control cells, whereas the majority of TF (∼70%) in
CHC siRNA-treated cells remained susceptible to trypsin even
after 15 min at 37 °C. This indicated that clathrin-dependent
endocytosis was compromised in the CHC siRNA-treated cells.
To determine the effect of CHC knock-down on endocytosis of
Pr55Gag, siRNA- or mock-transfected cells were infected with
NL4-3(Gag/ΔVpu), and at 24 h postinfection cells were
metabolically labeled with [35S]methionine for 30 min and
chased for 10 min or 180 min. Intact cells were then coated with
cationic silica beads at +4 °C prior to homogenization, and
crude cell extracts were fractionated on a Nycodenz step
gradient. The gradient consisted of a 70% Nycodenz cushion
and a 60% sample loading zone overlaid with 50% Nycodenz
and buffer solutions. This fractionation method efficiently
separates the plasma membrane from internal membranes, since
Fig. 2. Effect of CHC-specific siRNAs on virus assembly. Extracellular VLPs
(−), or VLPs tethered to the cell surface and released by trypsin treatment of cells
(+), were pelleted through a sucrose cushion and analyzed by SDS-
polyacrylamide gel electrophoresis. (A) VLPs from cells that expressed
unprocessed Pr55Gag in the absence of Vpu [NL4-3(Gag/ΔVpu)-infection].
Cells were metabolically labeled for 180 min. (B) VLPs from cells that
expressed Gag and Gag-Pol, but no Vpu [NL4-3(ΔVpu/ΔEnv)-infected cells].
Cells were metabolically labeled for 240 min. Only the CA form is shown, since
the VLPs did not contain significant amounts of unprocessed Pr55Gag or
processing intermediates of Gag.
Fig. 1. RNAi-mediated knock-down of CHC does not inhibit uptake of cell
surface-associated Pr55Gag, but reduces the uptake of Gag when Gag and Gag-
Pol are coexpressed. (A) The CHC-siRNA used effectively reduced the
intracellular levels of CHC. HeLa H1 cells were transfected with CHC-specific
siRNA (+) or mock-transfected (−). CHC levels in postnuclear supernatants
were probed by Western blotting, and GAPDH was used as a control to confirm
that equal amounts of siRNA- and mock-transfected samples were analyzed. (B)
Clathrin-mediated endocytosis was inhibited in the siRNA-transfected cells.
HeLa H1 cells were transfected with CHC-specific siRNA or mock-transfected
prior to infection with NL4-3(Gag/ΔVpu), and clathrin-mediated endocytosis
was probed by measuring the uptake of biotin-tagged transferrin. Transferrin
was bound to cells at 4 °C, and internalized at 37 °C for the indicated times. Cell
surface-associated transferrin was removed by trypsin prior to homogenization,
and the amount of endocytosed, trypsin-resistant transferrin in cell extracts was
determined by Western blotting. Tot sample was not trypsin-treated and it
indicates the amount of transferrin originally bound to cells. (C) CHC knock-
down does not inhibit endocytosis of Pr55Gag expressed in the absence of Vpu.
HeLa H1 cells were transfected with CHC-specific siRNA or mock-transfected
prior to infection with NL4-3(Gag/ΔVpu). Cells were metabolically labeled
with [35S]methionine for 30 min and chased for the indicated times. After the
chase, intact cells were coated with cationic silica beads at 4 °C prior to
homogenization, and crude cell extracts were fractionated on a Nycodenz step
gradient to separate the plasma membrane (PM) from internal membranes (I).
Pr55Gag proteins were immunoprecipitated from the PM and I fractions, and
immunoprecipitates were analyzed by SDS-polyacrylamide gel electrophoresis.
The 10 min CHC sample and the 180 min chase samples are from different
experiments. (D) Intracellular localization of Pr55Gag coexpressed with Vpu is
not affected by the knock-down of CHC. HeLa H1 cells were transfected with
CHC-specific siRNA and infected with NL4-3(Gag). Cells were metabolically
labeled for 30 min and chased for 150 min prior to silica coating and
fractionation. (E) Analysis of the effect of CHC knock-down on uptake of Gag
when Gag and Gag-Pol were coexpressed [NL4-3(ΔVpu/ΔEnv)-infected cells].
Cells were metabolically labeled for 30 min and chased for 120 min prior to
silica coating and fractionation.
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vesicles and membrane sheets pellet through the 70% Nycodenz
cushion during ultracentrifugation, whereas internal membranes
float to the 50% Nycodenz-buffer interphase (for controls, see
Harila et al., 2006). Distribution of labeled Pr55Gag between the
plasma membrane (PM) and internal membrane (I) fractions
was determined by immunoprecipitation and by gel electro-
phoresis analysis of the immunoprecipitates. As shown in Fig.
1C, the CHC siRNAs did not block redistribution of labeled
Pr55Gag from the cell surface to internal membranes. After
10 min of chase, the majority of labeled Pr55Gag was in the PM
fraction in CHC siRNA-transfected cells, whereas the labeled
Pr55Gag had shifted to I fraction in the siRNA-transfected cellsas efficiently as in mock-transfected control cells after 180 min
of chase. Thus, clathrin-mediated endocytosis is not involved in
uptake of plasma membrane-associated Pr55Gag in NL4-3(Gag/
ΔVpu)-infected HeLa H1 cells. Lowering intracellular levels of
CHC did not affect intracellular localization of Pr55Gag
coexpressed with Vpu, since the majority of labeled Pr55Gag
in NL4-3(Gag)-infected cells was found in the PM fraction even
after 150 min of chase (Fig. 1D).
The effect of CHC knock-down was also tested in the context
of Gag and Gag-Pol coexpression. CHC siRNA- or mock-
transfected HeLa H1 cells were infected with NL4-3(ΔVpu/
ΔEnv), a virus carrying defective vpu and env genes, and at
21 h postinfection cells were metabolically labeled with [35S]
methionine for 30 min and chased for 120 min. As shown in
Fig. 1E, only trace amounts of labeled, unprocessed Pr55Gag
remained in mock-transfected and siRNA-transfected cells after
the 120-min chase. Approximately ∼60% of p24 CA was
internal in mock-treated cells, whereas the internal p24
comprised ∼49% of total cell-associated CA in CHC siRNA-
treated cells. This small difference in the intracellular distribu-
tion of CA was reproducible.
The results in Figs. 1C and E suggested that the uptake of
plasma membrane-associated Gag in NL4-3(Gag/ΔVpu)-
infected cells was clathrin-independent, but in NL4-3(ΔVpu/
ΔEnv)-infected cells, a subpopulation of Gag might be
internalized by clathrin-mediated endocytosis. Alternatively,
as there is the strong possibility that Gag is endocytosed as a
fully assembled virion (Neil et al., 2006), the results in Figs. 1C
and E might reflect differential impact of CHC knock-down on
virus assembly in these two cells. To distinguish between these
possibilities, we analyzed production of VLPs from NL4-3
(Gag/ΔVpu)- and NL4-3(ΔVpu/ΔEnv)-infected cells contain-
ing normal or low intracellular levels of CHC. The NL4-3(Gag/
ΔVpu)- or NL4-3(ΔVpu/ΔEnv)-infected cells were metaboli-
cally labeled with [35S]methionine for 180 min and 240 min,
respectively, and VLPs released into the culture supernatant, or
VLPs tethered to the cell surface (=VLPs released after trypsin
treatment of cells) were purified by pelletation through a 20%
sucrose cushion. The amount of labeled Gag in the pellets was
determined by gel electrophoresis. As shown in Fig. 2A, only
trace amounts of labeled Pr55Gag were released into extra-
cellular VLPs from NL4-3(Gag/ΔVpu)-infected cells, but
Fig. 4. Filipin reduces retargeting of newly synthesized Gag from the cell surface
to internal membranes in infected HeLa H1 cells. (A) Cells expressing
unprocessed Pr55Gag in the absence of Vpu [NL4-3(Gag/ΔVpu)-infection] were
metabolically labeled for 30 min, and chased for 210 min in the presence or
absence of filipin prior to silica coating and fractionation. (B) Filipin does not
affect intracellular localization of Pr55Gag coexpressed with Vpu. NL4-3(Gag)-
infected cells were pulsed for 30 min and chased in the presence of filipin for
210 min. (C) Analysis of NL4-3(Gag/ΔVpu)-infected cells when filipin was
added after 30 min of chase. Cells were pulsed for 30 min and chased for 30 min
before addition of filipin. The chase in the presence or absence of filipin was
continued for further 180 min. (D) Similar analysis from NL4-3(ΔVpu/ΔEnv)-
infected HeLa H1 cells, which express Gag together with Gag-Pol, and no Vpu.
Filipin was added to the chase medium after 30 min of chase, and chase was
continued for further 180 min. The 30 min sample indicates intracellular
distribution of labeled Gag at the time of filipin addition.
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amounts of labeled Pr55Gag VLPs tethered to the cell surface.
Thus, the knock-down of CHC apparently did not affect virus
assembly in NL4-3(Gag/ΔVpu)-infected cells. In NL4-3
(ΔVpu/ΔEnv)-infection, small amounts of labeled CA were
detected in extracellular VLPs produced from control mock-
transfected cells, but the majority of labeled CA was found in
VLPs tethered to the cell surface (Fig. 2B). Knock-down of
CHC reduced incorporation of labeled CA into both the
extracellular VLPs and into VLPs that were tethered to the cell
surface. Quantitations from two different experiments sug-
gested that total VLP production was ∼3-fold higher in mock-
transfected control cells than in CHC siRNA-transfected cells.
However, this could be an overestimation, since the VLP assay
did not take into account internal (or internalized) VLPs. Since
the mock-transfected and CHC siRNA-transfected cells had
similar amounts of membrane-associated Gag and since there
was no indications that low intracellular levels of CHC caused
any Gag processing defects (Fig. 1E), the CHC siRNAs
apparently did not reduce membrane targeting or higher-order
multimerization of newly synthesized Gag in NL4-3(ΔVpu/
ΔEnv)-infected cells, but produced an as-yet-undefined mod-
erate late assembly defect in these cells. This late assembly
defect might explain why CHC siRNAs gave slightly different
results in NL4-3(Gag/ΔVpu)- and NL4-3(ΔVpu/ΔEnv)-
infected cells in the cell fractionation experiments.
We next tested whether the endocytic uptake of Gag in
ΔVpu-virus background occurred by macropinocytosis. If
macropinocytosis was involved, virus infection would need to
stimulate this uptake mechanism, since macropinocytosis is not
a constitutive feature of HeLa cells. We measured the uptake of
fluorescein-conjugated dextran into noninfected, NL4-3(Gag)-
or NL4-3(Gag/ΔVpu)-infected HeLa H1 cells in order to
determine whether macropinocytosis was upregulated in
infected HeLa H1 cells. Flow cytometric analyses indicated
similar low levels of macropinocytosis for all three cell
populations (data not shown). The effect of 5-(N-ethyl-N-
isopropyl) amiloride, a potent inhibitor of induced macropino-
cytosis (Meier et al., 2002; West et al., 1989), was tested in Fig.
3. NL4-3(Gag/ΔVpu)-infected cells were pulsed for 30 min,
and chased for 180 min in the presence or absence of 100 μM
amiloride. As shown in Fig. 3, amiloride did not block the shift
of labeled Pr55Gag from the PM to the I fraction in NL4-3(Gag/
ΔVpu)-infected cells. Thus, the uptake of Gag in the ΔVpu-
virus background is unlikely to occur by a macropinocytosis-
like activity.Fig. 3. The inhibitor of induced macropinocytosis, 5-(N-ethyl-N-isopropyl)
amiloride, did not block shift of newly synthesized Pr55Gag from the plasma
membrane to internal membranes in NL4-3(Gag/ΔVpu)-infected HeLa H1 cells.
Infected cells were pulsed for 30 min, and chased for 180 min in the presence or
absence of amiloride prior to silica coating and fractionation.Effect of filipin on the uptake of cell surface-associated Gag
The possible dependence of Pr55Gag endocytosis on
cholesterol was tested by filipin, an antibiotic commonly
used to disrupt cholesterol-dependent raft-like microdomains at
the cell surface. NL4-3(Gag/ΔVpu)-infected HeLa H1 cells
were metabolically labeled with [35S]methionine for 30 min
and chased for 210 min in the presence or absence of filipin
(3 μg/ml). This amount of filipin did not induce extensive
shedding of microvesicles (a common side-effect of removal of
cell surface cholesterol), but the filipin concentration was
sufficient to inhibit cholesterol-dependent endocytic processes,
since the clathrin-mediated uptake of transferrin was inhibited
in filipin-treated cells (data not shown; Subtil et al., 1999). As
shown in Fig. 4A, filipin treatment considerably reduced the
amount of labeled Pr55Gag in I fraction after 210 min of chase:
quantitations from two separate experiments indicated that
approximately 61% of labeled Pr55Gag was detected in the I
fraction in untreated cells whereas only ∼19% of labeled
Pr55Gag was in internal membranes in filipin-treated cells.
Filipin treatment did not change intracellular localization of
Pr55Gag that was coexpressed with Vpu [NL4-3(Gag)-infec-
tion], since, as in untreated cells (Harila et al., 2006) the
majority of labeled Pr55Gag in filipin-treated cells were plasma
membrane-associated after 210 min of chase (Fig. 4B).
The results in Fig. 4A suggested that the endocytic uptake of
Pr55Gag could occur by a cholesterol-dependent mechanism.
However, cholesterol is also required for efficient membrane
binding and higher-order multimerization of HIV-1 Gag (Ono
et al., 2007). Since there are strong indications that Gag is
endocytosed as a fully assembled virion (Neil et al., 2006), the
observed effect of filipin could be due to inability of plasma
Fig. 5. Analysis of intracellular targeting of newly synthesized Pr55Gag in
subconfluent HeLa H1 cell cultures. (A) Confluent or subconfluent cells
expressing unprocessed Pr55Gag in the absence of Vpu [HXB2D-(Gag)-
infection]. Cells were metabolically labeled for 30 min and chased for the
indicated times prior to silica coating and fractionation. In contrast to confluent
cells, newly synthesized Pr55Gag was simultaneously detected in PM and I
fractions in the subconfluent cell cultures. (B) Cells coexpressing Vpu and
unprocessed Pr55Gag [NL4-3(Gag)-infection] were analyzed after a 30 min pulse
and a 5 min chase. Newly synthesized Pr55Gag coexpressed with Vpu was
primarily targeted to the plasma membrane in subconfluent cells. (C) Cells
expressing an endocytosis-defective Pr55Gag/HA [HXB2D-(GagHA)-infected
cells]. Cells were analyzed after a 30 min pulse and a 5 min chase. No Vpu was
expressed in the HXB2D-(GagHA)-infected cells.
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the presence of the drug. To test this possibility, we added filipin
after 30 min of chase, i.e. at the time when maximal membrane
insertion, as well as at least some higher-order multimerization
of labeled Pr55Gag has already occurred (Ono et al., 2007; Tritel
and Resh, 2000). As shown in Fig. 4C, filipin added after 30 min
of chase reduced the amount of labeled Pr55Gag in I fraction at
the 210 min chase point, but the reduction was less than if filipin
was present from the beginning of chase. In the experiment
shown in Fig. 4C, ∼37% and 49% of labeled Pr55Gag was in
internal membranes in filipin-treated and untreated cells,
respectively. However, the efficiency with which filipin
inhibited the uptake of Pr55Gag varied between different
experiments; the relative amount of labeled Pr55Gag in the I
fraction was 12%–32% lower in filipin-treated cells than in
control untreated cells. To further probe the possibility that
filipin exerted its effect primarily through inhibiting multi-
merization of Gag, we also tested the impact of filipin in the
context of Gag and Gag-Pol coexpression, since processing of
Pr55Gag offers a convenient indirect marker for efficient
multimerization of Gag (Kaplan et al., 1994). HeLa H1 cells
were infected with NL4-3(ΔVpu/ΔEnv)-virus, pulsed for
30 min, and filipin was added after 30 min of chase, and the
chase was continued for further 180 min. At the time of filipin
addition (Fig. 4D; 30 min), the PM fraction contained large
amounts of labeled Pr55Gag, whereas the small amounts of
processed CA forms were ∼equally distributed between the PM
and I fractions. After 210 min of chase, only trace amounts of
unprocessed Pr55Gag were present in untreated control cells, and
68% of labeled CAwas in the I fraction. In contrast, the filipin-
treated cells contained significant amounts of plasmamembrane-
associated, unprocessed Pr55Gag at the 210 min chase point, thus
suggesting that filipin affected proper higher-order multimeriza-
tion of Gag. Approximately 47% of total cell-associated labeled
CAwas in internal membranes after 210 min of chase. However,
in another experiment, CA in filipin-treated cells distributed to
the I fraction as efficiently as in untreated control cells (data not
shown). Thus, the effect of filipin varied between different
experiments, but overall, filipin had a relatively minor effect on
intracellular distribution of CA. Therefore, a significant part of
the apparent reduction in Gag uptake in the filipin-treated cells
might be attributable to the inhibitory effects of filipin on higher-
order oligomerization of Gag.
The apparent targeting phenotype of newly synthesized Gag is
different in confluent and subconfluent HeLa H1 cultures
As mentioned in the Introduction, attempts to analyze
intracellular targeting of newly synthesized HIV-1 Gag have
produced contradictory results. The results in our previous
publication (Harila et al., 2006), as well as for example Figs. 1C
and 4D above, clearly indicate that a newly synthesized Gag is
initially inserted into the plasma membrane in HeLa H1 cells.
These results were from confluent HeLa H1 cells, but the
trafficking phenotype of newly synthesized Gag turned out to be
different when we repeated the targeting analyses in subcon-
fluent HeLa H1 cell cultures (∼30–40% confluency). Fig. 5Ashows analysis of confluent and subconfluent HeLa H1 cells
infected with HXB2D-(Gag), a recombinant virus with a
defective Pol region, a defective vpu gene, and a truncated nef
gene. The infected cells were metabolically labeled with [35S]
methionine for 30 min, and chased for 5 min or 240 min. In
confluent cells, the majority of newly synthesized Pr55Gag was
at the plasma membrane after 5 min of chase, but in sub-
confluent cells, labeled Pr55Gag was simultaneously detected in
PM and I fractions. Whereas there was a clear increase of
labeled Pr55Gag in the I fraction in confluent cells after 240 min
of chase, the amount of labeled Pr55Gag in I fraction in
subconfluent cells increased only slightly during a longer chase
(∼60% was internal after 240 min of chase). When expressed in
the presence of Vpu [NL4-3(Gag)-genome], the majority of
newly synthesized Pr55Gag was in the PM fraction in both
subconfluent (Fig. 5B; a 30 min pulse and a 5 min chase) and in
confluent cell cultures (Harila et al., 2006). The simultaneous
detection of Pr55Gag in the PM and I fraction in HXB2D-(Gag)-
infected subconfluent cells could mean that membrane insertion
of newly synthesized Pr55Gag expressed in the absence of Vpu
was random in subconfluent cultures, or, alternatively, that
uptake of plasma membrane-associated Pr55Gag occurred very
rapidly in these cells. To distinguish between these possibilities,
we tested targeting of Pr55Gag/HA in subconfluent cells.
Pr55Gag/HA contains a carboxyterminal HA tag, and this Gag
variant is not endocytosed after insertion into the plasma
membrane when expressed in the absence of Vpu (Harila et al.,
2006). Fig. 5C shows analysis of HXB2D-(GagHA)-infected
subconfluent HeLa H1 cells after a 30 min pulse and a 5 min
chase. The majority of newly synthesized Pr55Gag/HA was
detected in the PM fraction. Similar distribution was observed
after 240 min of chase (data not shown). Taken together, these
results indicate that cell confluency can have an impact on the
304 K. Harila et al. / Virology 369 (2007) 299–308targeting phenotype of newly synthesized Gag when the protein
is expressed in the absence of Vpu.
Discussion
We have previously shown that a newly synthesized HIV-1
Gag is inserted into the plasma membrane in infected HeLa H1
cells, but the final steady-state localization of the protein is
influenced by Vpu; if coexpressed with Vpu, the majority of
Gag stays at the cell surface, but in the absence of Vpu, a
significant fraction of the cell surface-associated Gag proteins is
subsequently endocytosed into an endosome-like compartment
(Harila et al., 2006). Initial analysis of this Vpu-regulated
uptake indicated that the endocytosis of Gag required interac-
tion of Gag with the host protein Tsg101 (Harila et al., 2006; see
also Neil et al., 2006]. In the present study, we have further
studied the endocytic phenotype of Gag in HeLa H1 cells. As
discussed below, our interpretation of the results is that the
uptake of Gag in ΔVpu-virus background is clathrin-indepen-
dent and indirectly cholesterol-dependent, and cell density
influences kinetics of the uptake. This interpretation is based on
the assumption that the plasma membrane-associated Gag is
endocytosed as a fully assembled virion. Neil et al. (2006)
demonstrated that viruses produced in the absence of Vpu have
surface components that tether the nascent virions to the cell
surface after budding, and they suggested that the endosomal
Gag in ΔVpu-background arises from uptake of these tethered
virions. This suggestion was based on the observations that (1)
endosomal particles were mature in morphology, (2) coexpres-
sion of Gag/Gag-Pol with a mutant Rab5a, which reduced the
amount of endosomal Gag, resulted in accumulation of fully
assembled virions at the cell surface, and (3) Gag-mutants
unable to complete budding were only detected at the plasma
membrane. It is difficult to firmly establish whether Gag in
HeLa H1 cells is endocytosed as a fully assembled virion, or as
a smaller assembly intermediate. However, observations that the
uptake of Gag in HeLa H1 cells can be reduced by depletion of
Tsg101, by cycloheximide (data not shown), or by addition of a
HA tag to the carboxyterminus of Pr55Gag (Harila et al., 2006),
are consistent with fully assembled virions being the targets of
the uptake mechanism, since all of these conditions interfere
with virus assembly (data not shown; Garrus et al., 2001;
Martin-Serrano et al., 2001).
We used RNAi-mediated knock-down of CHC to determine
whether the endocytosis of Gag occurred by a clathrin-
dependent or a clathrin-independent mechanism. The results
from these knock-down experiments indicated that the CHC-
specific siRNA used did not inhibit uptake of Pr55Gag in NL4-3
(Gag/ΔVpu)-infected cells, although the endocytosis of trans-
ferrin was measurably inhibited in these knock-down cells.
Overall, the uptake of Pr55Gag in CHC knock-down cells
occurred with similar kinetics and efficiency as uptake of Gag in
mock-transfected cells (i.e. in cells treated only with the
transfection reagent), or in untreated HeLa H1 cells (data not
shown). However, the CHC-specific siRNA produced a
relatively minor, but reproducible reduction in the uptake of
Gag (p24) in NL4-3(ΔVpu/ΔEnv)-infected cells. These resultscould mean that the uptake of unprocessed Gag differs from that
of Gag expressed together with Gag-Pol. However, if plasma
membrane-associated Gag is endocytosed as a virion, the
discordant results from NL4-3(Gag/ΔVpu)- and NL4-3
(ΔVpu/ΔEnv)-infected cells could be due to the fact that virus
assembly in NL4-3(Gag/ΔVpu)-infected cells appeared to be
insensitive to knock-down of CHC, whereas low intracellular
levels of CHC clearly reduced virus formation in NL4-3(ΔVpu/
ΔEnv)-infected cells. Therefore, our interpretation of the
experimental data is that the uptake of Gag is clathrin-
independent. This conclusion is in agreement with a recent
report demonstrating that endocytosis of Gag in 293Tcells is not
blocked by chlorpromazine, a drug that inhibits clathrin-
mediated endocytosis (Finzi et al., 2007). At present it is unclear
why the knock-down of CHC reduced virus assembly in NL4-3
(ΔVpu/ΔEnv)-infected cells, but apparently some very late step
in the assembly was affected since processing of Pr55Gag was not
impaired by the CHC siRNA.
Our results from filipin-treated cells demonstrate that
interfering with plasma membrane cholesterol reduces uptake
of cell surface-associated Gag inΔVpu-virus background. HIV-
1 Gag is considered to be a raft-associated protein, and raft-like
microdomains at the plasma membrane have been suggested to
function as platforms for virus assembly (Ding et al., 2003;
Halwani et al., 2003; Holm et al., 2003; Lindwasser and Resh,
2001; Nguyen and Hildreth, 2000; Ono and Freed, 2001; Zheng
et al., 2001). The observed effects of filipin could mean that the
uptake of Gag occurs by a cholesterol-dependent, raft-mediated
mechanism. However, filipin efficiently reduced the uptake
only when added at the beginning of chase. Adding filipin after
30 min of chase produced a less pronounced inhibition.
Furthermore, filipin had a variable and a relatively minor effect
on intracellular distribution of CA. These observations could
indicate that the uptake mechanism of Gag is only indirectly
dependent on cholesterol. It has been shown that cholesterol is
required for efficient membrane binding and higher-order
oligomerization of HIV-1 Gag (Ono et al., 2007), and if virions
tethered to the cell surface are the form in which Gag is
endocytosed, then anything that interferes with virus assembly
affects the uptake of Gag as well. Filipin in our experiments
most likely reduced the overall virus assembly, since processing
of Pr55Gag was impaired in the NL4-3(ΔVpu/ΔEnv)-infected
cells. Thus, the inhibitory effect of filipin on Gag uptake might
reflect reduced virus assembly rather than the uptake mechan-
ism being cholesterol-dependent.
The uptake of Gag in our experimental setting was not
inhibited by 5-(N-ethyl-N-isopropyl) amiloride, an inhibitor of
induced macropinocytosis. Thus, none of the three inhibitors
(filipin, CHC siRNA, amiloride) directed against cholesterol-
dependent uptake, clathrin-mediated endocytosis, or macro-
pinocytosis produced a clear-cut inhibition of Gag uptake in the
ΔVpu-virus background. This raises the possibility that the Gag
uptake could occur by the poorly characterized clathrin- and
lipid raft-independent uptake pathways (Pelkmans andHelenius,
2003). The uptake of Gag is unlikely to be caveolae-mediated,
since (1) intracellular accumulation ofΔVpu-viruses is also seen
in T cells which do not express caveolin (Klimkait et al., 1990),
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structures are rare in these cells, and genistein, an inhibitor of
caveolae-mediated endocytosis (Pelkmans and Helenius, 2003),
does not affect endocytosis of Gag (data not shown). Our further
observations suggest that interaction of the MA domain of Gag
with AP-3 δ subunit, or the Y84G substitution in the MA
domain, does not play a key role in the Vpu-regulated
endocytosis of Gag in HeLa H1 cells (data not shown), although
both the AP-3 δ subunit and the Y84G substitution have
previously been shown to affect targeting of HIV-1 Gag to
endosomal compartments (Dong et al., 2005; Ono and Freed,
2004). We have not been able to test dependence of the Gag
uptake on actin dynamics, since treatment of infected cells with
for example jasplakinolide, latrunculin B, or cytochalasin D
disrupts the cells during silica coating (data not shown).
Our interpretation that uptake of Gag is mediated by a
clathrin-independent mechanism is seemingly contradictory to
the report that dominant negative forms of dynamin, EPS-15,
and Rab5a, all known inhibitors of clathrin-mediated endocy-
tosis, prevent endocytosis of Gag in HeLa cells (Neil et al.,
2006). However, a dominant negative approach and RNAi do
not always give the same results, as exemplified by the
observations that dominant-negative CHMP5, but not depletion
of endogenous CHMP5, inhibits HIV-1 release (Martin-Serrano
et al., 2001; Ward et al., 2005). A dominant-negative mutant can
inhibit a cellular function indirectly, for example, by perturbing
more than one cellular pathway due to inactivation of essential
factors that operate at more than one cellular site. Another
possibility is that the uptake mechanism of Gag is cell type-
dependent. Assuming that Gag is endocytosed as a fully-
assembled virions, our results from e.g. NL4-3(ΔVpu/ΔEnv)-
infections indicate that the endocytosis process is directed by
cellular factors present in the viral envelope, not the viral Env
protein. The HIV-1 envelope contains several different cellular
proteins (Chertova et al., 2006; Hammarstedt and Garoff, 2004),
and subtle cell type-dependent changes in the composition of
the virion envelope could specify the efficiency of ΔVpu-virus
uptake, and perhaps also the mechanism of the uptake.
Our previous (Harila et al., 2006) and present results indicate
that the Vpu-regulated endocytosis of Gag is a key determinant
for the steady-state localization of Gag and VLPs in HeLa H1
cells. Vpu most likely controls targeting of Gag in infected T
cells as well, since deletion of vpu gene results in accumulation
of virions into intracellular compartments of these cells
(Klimkait et al., 1990). In contrast, concentration of Gag and
progeny virions into the internally sequestered plasma mem-
brane domains in macrophages is Vpu-independent (Deneka et
al., 2007; Pelchen-Matthews et al., 2003; Welsch et al., 2007).
However, the intracellular virus-containing vacuoles of macro-
phages and T cells or HeLa H1 cells are different, since the
limiting membrane of Jurkat and HeLa H1 virus-containing
vacuoles is not stained with the cell-impermeant dye ruthenium
red (data not shown), and the vacuoles thus belong to the
endosomal network. In general, intracellular trafficking routes
that control cell surface versus endosomal localization of Gag
and VLPs have been the subject of intense debates. Only few
serious attempts have been made to characterize the intracellulartransport of a newly synthesized Gag (Finzi et al., 2007;
Grigorov et al., 2006; Harila et al., 2006; Jouvenet et al., 2006;
Neil et al., 2006; Perlman and Resh, 2006; Rudner et al., 2005),
and results from these studies are conflicting. Cell fractionation
analyses by us (Harila et al., 2006) and Finzi et al. (2007), as
well as FlAsh/ReAsh imaging studies by Rudner et al. (2005) or
fluorescence microscopy analyses of cells expressing Gag-GFP
(Jouvenet et al., 2006; Neil et al., 2006), indicated that a newly
synthesized Gag in HeLa H1, HeLa, 293 T cells, or
macrophages was initially inserted into the plasma membrane.
In contrast, FlAsh/ReAsh cell imaging studies by Perlman and
Resh (2006) implied a ‘perinuclear’ and endosomal transport
intermediates for cell surface Gag in HeLa, Cos-1, and Jurkat T
cells. Cell fractionation studies by Grigorov et al. (2006) in turn
demonstrated that newly synthesized Gag proteins in 293 Tcells
were simultaneously detected at the plasma membrane and on
endosomal membranes. One explanation for these contradictory
results can be the different expression systems used, since the
above-mentioned studies utilized either proviral expression of
Gag or codon-optimized plasmid-driven expression of Gag. At
least three proteins of HIV-1, Nef, Gag, and Vpu, can
potentially modulate membrane trafficking pathways of the
host cell through interactions with cellular partners (Batonick et
al., 2005; Costa et al., 2006; Dong et al., 2005; Madrid et al.,
2005; Varthakavi et al., 2006), and thus intracellular targeting of
Gag could be different in virus-infected cells and in cells in
which a plasmid-driven expression system is used for synthesis
of Gag. Even the multiplicity of infection and/or the time point
postinfection could impact the apparent targeting phenotype of
Gag. Our present study demonstrates that another important
factor to consider in targeting analyses of Gag is the confluency
of cell cultures; in confluent HeLa H1 cells, newly synthesized
Gag was first detected at the plasma membrane in both Vpu+
and ΔVpu-virus backgrounds, whereas in subconfluent HeLa
H1 cultures, Gag expressed in the absence of Vpu appeared
simultaneously in both the plasma membrane and internal
membrane fractions. The molecular basis of this phenomenon is
unclear at present. It is difficult to determine whether the newly
synthesized internal Gag population in subconfluent cells
represents Gag proteins directly inserted into the internal
membranes, or proteins (rapidly) endocytosed from the cell
surface. We favor the latter alternative, because (1) the majority
of newly synthesized Gag coexpressed with Vpu fractionated
with the plasma membrane fraction, and *2) newly synthesized
Pr55Gag/HA, which is not endocytosed when expressed in the
absence of Vpu, was detected at the plasma membrane in
subconfluent cultures as well. Overall, the results from the
subconfluent cells stress the need to monitor targeting of Gag
with assays that can detect rapid, dynamic changes in
intracellular localization of Gag.
Materials and methods
Cell culture, viruses, and plasmid constructs
HeLa H1 and 293T cells were cultured as previously
described (Harila et al., 2006; Holm et al., 2003). Production
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as well as plasmid constructs for NL4-3(Gag/ΔVpu), NL4-3
(Gag), HXB2D-Gag, and HXB2D-GagHA has been previously
described (Harila et al., 2006). Plasmid pNL4-3(ΔVpu/ΔEnv),
a derivative of pNL4-3 (Adachi et al., 1986), contains defective
vpu and env genes, and a truncated vpr gene. The plasmid was
constructed by replacing the 6459-bp ApaI–BamHI fragment of
pNL4-3 with the equivalent ApaI–BamHI fragment of
pHXB2D-(ΔVpu/ΔEnv) (Harila et al., 2006).
Subcellular fractionations
HeLa H1 cells on 10-cm plates were infected with VSV-G-
pseudotyped recombinant HIV-1 (∼1–5 infectious units/cell),
and at ∼21 h [NL4-3(ΔVpu/ΔEnv)-virus] or ∼24 h [NL4-3
(Gag/ΔVpu)-virus], postinfection cells were metabolically
labeled with [35S]methionine for 30 min and chased for various
times as previously described (Holm et al., 2003). After the
chase, cells were brought into suspension by incubation in
phosphate-buffered saline (PBS) containing 0.02% EDTA
(PBS-EDTA), intact cells were coated at 4 °C with cationic
silica beads, and cell extracts were fractionated on a Nycodenz
step gradient as previously described (Harila et al., 2006). Gag
proteins were immunoprecipitated from sodium dodecyl sulfate
(SDS)-solubilized plasma membrane and internal membrane
fractions with mouse anti-HIV-1 CA monoclonal antibody 38:9
(Hinkula et al., 1990), or with a mixture of the 38:9 antibody
and a mouse monoclonal anti-p24 antibody 32/5.17.76 (Abcam,
Ltd.). The HA-tagged Gag was immunoprecipitated with a
rabbit polyclonal anti-HA antibody (Sigma).
In filipin treatment, the chase medium contained 3 μg of
filipin complex (Sigma) per ml. In 5-(N-ethyl-N-isopropyl)
amiloride treatment, 100 μM of the drug (Alexis Biochemicals)
was included into the chase medium. To measure macropino-
cytosis, cells were first preincubated in minimum essential
medium containing 0.2% BSA (MEM-BSA) for 30 min, and
then shifted to MEM-BSA containing 1 mg per ml of lysine-
fixable fluorescein isothiocyanate-conjugated dextran (70,000
Da, Molecular Probes) for 10 min. After extensive washing,
cells were incubated in MEM-BSA for further 5 min. To strip
plasma membrane-associated dextran, cells were placed on ice
and incubated for 5 min in a pH 5.5 buffer containing 100 mM
sodium acetate and 50 mM sodium chloride. After washes with
ice-cold PBS, cells were detached from plates by incubation in
PBS-EDTA on ice for 20 min, fixed with 2% paraformaldehyde,
and analyzed by a fluorescence-activated cell sorter.
VLPs
To analyze the efficiency of VLP production, NL4-3(Gag/
ΔVpu)-infected HeLa H1 cells were metabolically labeled with
[35S]methionine for 180 min, and NL4-3(ΔVpu/ΔEnv)-
infected cells were metabolically labeled for 240 min. Cell
culture supernatants were collected, filtered (0.45 μm), layered
on to a 20% sucrose cushion (w/v, in 25 mM HEPES pH 7.4,
150 mMNaCl, 2 mMMgCl2), and centrifuged at 100,000×g for
60 min. Pellets were analyzed by gel electrophoresis. Thesepellets represented constitutively released extracellular parti-
cles. To analyze the amount of VLPs tethered to the cell surface,
cells were washed once with PBS after harvesting culture
supernatants, and incubated with trypsin (0.5 mg/ml) at 37 °C
for 10 min. The reaction was stopped by adding culture medium
containing 7% fetal bovine serum, cells were pelleted and
culture supernatants were filtered, and VLPs were pelleted
through sucrose as described above.
RNAi
Short interfering RNAs (siRNAs) directed against the
clathrin heavy chain (CCUGCGGUCUGGAGUCAACdTdT;
40 pmol per 10-cm plate; Hinrichsen et al., 2003) were
transfected into HeLa H1 cells by using siLentFect (BioRad) in
accordance with the manufacturer's instructions. Mock-trans-
fected cells were treated with siLentFect alone. At about 22 h
posttransfection, the cells were infected and analyzed about
21–24 h postinfection. Intracellular levels of clathrin heavy
chain in mock- and siRNA-treated cells were determined from
postnuclear supernatants of cell extracts by Western blotting
with a polyclonal goat anti-clathrin heavy chain antibody
(C-20; Santa Cruz Biotechnology, Inc.). The polyclonal anti-
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) anti-
body (FL-335; Santa Cruz Biotechnology, Inc.) was used as
a control.
To analyze the effect of CHC knock-down on clathrin-
mediated endocytosis, NL4-3(Gag/ΔVpu)-infected HeLa H1
cells, mock- or siRNA-treated, were washed once with PBS
(with MgCl2 and CaCl2) containing 0.2% bovine serum
albumin (PBS-BSA), and cells were incubated for 30 min on
ice in PBS-BSA containing 500 ng/ml human biotin-tagged
transferrin (Sigma). After washing the unbound transferrin
away, minimum essential medium containing 0.2% BSA was
added to cells and cells were shifted to 37 °C for 0 min, 5 min,
or 15 min. Cells were then placed on ice, treated with acid wash
buffer (0.2 M sodium acetate buffer pH 4.5, 0.5 M NaCl) for
2 min, rinsed with the acid wash buffer, and washed with excess
PBS-BSA and PBS. Cell surface-associated transferrin was
removed by trypsin treatment (20 min on ice). Trypsin was
inactivated by culture medium containing 7% fetal bovine
serum, cells were homogenized, and postnuclear supernatants
of cell extracts were prepared as previously described (Harila et
al., 2006). The amount of trypsin-resistant transferrin–biotin in
postnuclear supernatants was determined by Western blotting
using streptavidin–peroxidase polymer (Sigma).
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